Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OPEN TRIAL OF INTRAVENOUS IMMUNE SERUM GLOBULIN FOR CHRONIC SINUSITISIN CHILDREN
Autore:
RAMESH S; BRODSKY L; AFSHANI E; PIZZUTO M; ISHMAN M; HELM J; BALLOW M;
Indirizzi:
SUNY COLL BUFFALO,CHILDRENS HOSP BUFFALO,DEPT PEDIAT,DIV CLIN IMMUNOL& ALLERGY,219 BRYANT ST BUFFALO NY 14222 SUNY COLL BUFFALO,CHILDRENS HOSP BUFFALO,DEPT PEDIAT OTOLARYNGOL BUFFALO NY 14222 NIAGARA UNIV,DIV MANAGEMENT SCI NIAGARA NY 14109
Titolo Testata:
Annals of allergy, asthma, & immunology
fascicolo: 2, volume: 79, anno: 1997,
pagine: 119 - 124
SICI:
1081-1206(1997)79:2<119:OTOIIS>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
IGG-SUBCLASS DEFICIENCY; CAPSULAR POLYSACCHARIDE ANTIGEN; SELECTIVE ANTIBODY DEFICIENCY; GAMMA-GLOBULIN; THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN; INVITRO; THERAPY; INFLAMMATION; ASTHMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
33
Recensione:
Indirizzi per estratti:
Citazione:
S. Ramesh et al., "OPEN TRIAL OF INTRAVENOUS IMMUNE SERUM GLOBULIN FOR CHRONIC SINUSITISIN CHILDREN", Annals of allergy, asthma, & immunology, 79(2), 1997, pp. 119-124

Abstract

Background: Chronic sinusitis in children is a complex clinical problem. Some patients do not improve with medical therapy and some fail surgery as well. Objective: A therapeutic trial of intravenous immune serum globulin (IVIG) was given to children whose sinus disease was recalcitrant to the usual therapeutic modalities. The objective of IVIG administration was to modulate the inflammatory process contributing to the chronicity of the sinusitis. Methods: Six patients were given a 12-month trial of monthly (400 mg/kg) IVIG infusions. Entry criteria included persistence of sinusitis after 3 months of full course antibiotics, or two episodes of sinusitis within a 3-month period while on prophylactic antibiotics. All patients had abnormal sinus CT (computerizedtomography) scans at entry. Three of the six patients remained symptomatic despite prior sinus surgery. Patients with primary immune deficiencies were excluded. Each patient served as his own control based on their previous 12-month history and clinical course. Four of the 6 patients were atopic as demonstrated by prick skin testing; however, all patients had nasal eosinophilia. Results: Full course antibiotic use decreased in five of the six patients (183 to 84 days); correspondingly, the episodes of sinusitis decreased (average 9 to 4 per year). In addition, sinus CT scans showed significant improvement. Conclusion: This preliminary open-trial of IVIG suggests its usefulness as adjunct therapy to medical management in selected patients with chronic sinus disease. The mechanism(s) by which IVIG may be helpful is probably not based on the concept of replacement therapy, but more likely as an immune or inflammatory modulating agent.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 15:33:25